1 Moccetti T. Zur Epidemiologie der Koronarsklerose 1939 – 1965. Inaugural – Dissertation 1966
2 Moccetti T, Albert H, Bühlmann A, Senning A, Lichtlen P. Haemodynamics after mitral valvotomy. Reasons for unsatisfactory clinical results. Br Heart J. 1972;34(5):493–502 . http://dx.doi.org/10.1136/hrt.34.5.493 PubMed
3 Lichtlen P, Moccetti T, Halter J. Zur Prognose der Koronarsklerose, beurteilt an Hand der koronarographischen Befunde. Schweiz Med Wochenschr. 1972;102(12):425–8. PubMed
4 Moccetti T, Lichtlen P, Minale C, Halter J, Schönbeck M, Meier W, et al.Bypass aorto-coronarico con „graft“ di vena safena (108 casi). Risultati clinici, angiografici, funzionali a distanza. G. ital. Card.1972;2:644.
5 Moccetti T, Lichtlen P, Rutishauser W, Schönbeck M, Meier W, Senning A. Klinische, angiographische und funktionelle Ergebnisse beim aorto-koronaren Venenbypass (140 Patienten). Schweiz Med Wochenschr. 1973;103(8):323‒7.
6 Casanova G, Spinelli R, Moccetti T. Cardiomobile con personale paramedico specializzato: Nostre esperienze dall’agosto 1974 al giugno 1982 (1262 interventi). Tribuna Medica Ticinese. 1983;12:526.
7 Moccetti T, Riva A, Clara F, Tartini R, Naegeli U, Molo C, et al.Klinische Erfahrungen mit der intraaortalen Ballonpumpe. Schweiz Med Wochenschr. 1982;112(37):1286–9. PubMed
8 T. Moccetti Aspetti attuali e sviluppi storici nell’impiego di pace-maker Esperienza di 300 impianti, con particolare riguardo ai pacemaker fisiologici Rivista Medica della Svizzera Italiana pag. 341, 1982
9 T. Moccetti, S. Martinoli, E. Pasotti, S. Lechuga, K.Smickovski, A. Riva, F. De’ Clari Pacemaker definitivi: esperienza di 20 anni e di oltre 1000 pacemaker impiantati all’OCL Tribuna Medica Ticinese, 58, aprile 1993
10 Gutzwiller F, Junod B, Schweizer W, et al.Die Epidemiologie der Risikofaktoren für kardiovaskuläre Krankheiten in der Schweiz. Schweiz Med Wochenschr.1981 (Suppl);12.
11 F. Barazzoni, C. Bernasconi, F. Gutzwiller, T. Moccetti, G. Noseda, C.F. Beretta-Piccoli I fattori di rischio cardiovascolare nel Ticino Progetto MONICA-Ticino Tribuna Medica Ticinese, 52, settembre 1987
12 Moccetti T. Kardiotoxische Medikamente unter besonderer Berücksichtigung der Phoenothiazine und Imipraminderivate. Verlag Hans Huber, Bern, Stuttgart, Wien 1977
13 M. Genoni, R. Malacrida, P. Siegrist, G. Garzoli, F. Sessa, A. Maggioni, T. Moccetti, ISIS-Studiengruppe Schweiz 3 Jahre Follow-up des ISIS-4 Patientenkolletivs in der Schweiz Schweiz. Med. Wochenschr. 1997; 127: suppl. 85
14 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349–60. PubMed
15 GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lancet. 1990;336(8707):65–71. PubMed
16 ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet. 1992;339(8796):753–70. PubMed
17 Enzo Fontana, Tiziano Moccetti, Cardiocentro Ticino, Lugano; Luigi Santoro, Inst. Mario Negri, Milano; Aldo P. Maggioni, Anmco Research Ctr, Florence; on Behalf of GISSI-2 Investigators High-Risk Patients and Complications Following MI Severe Congestive Heart Failure (CHF) and Cardiogenic Shock (CS) after Acute Myocardial Infartction (AMI): Incidence, Predicting Factors and Six-Month Mortality in Patients Without Hemodynamic Impairment at Entry. A GISSI-2 Trial Subanalysis Circulation Supplement II Vol. 102, No 18 October 31, 2000
18 Moccetti T, Malacrida R, Pasotti E, Sessa F, Genoni M, Barlera S, et al.Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database. Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-2). Arch Intern Med. 1997;157(8):865–9 . http://dx.doi.org/10.1001/archinte.1997.00440290049005 PubMed
19 Malacrida R, Genoni M, Maggioni AP, Spataro V, Parish S, Palmer A, Collins R, Moccetti T. A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med. 1998 Jan 1;338(1):8-14.
20 Gallino A, Moccetti T, Hirzel H, Meier B. A Man With a 40-Year Event-Free Follow-Up After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018;11(9):911 . http://dx.doi.org/10.1016/j.jcin.2018.02.003 PubMed
21 Del Bufalo E, Pasotti A, Rossi D, Moccetti T. The Swiss south-of-the Alps Experience in 1000 PTCA with out-of Hospital Surgical stand-by. Presentazione del poster SGK. Kardiovaskuläre Medizin 1999; 2: Suppl 1
22 Faletra FF, Pedrazzini G, Pasotti E, Moccetti T. Real-time three-dimensional transoesophageal echocardiography showing sequential events of the percutaneous mitral clip procedure. Eur Heart J. 2009;30(18):2225 . http://dx.doi.org/10.1093/eurheartj/ehp236 PubMed
23 Faletra FF, Pedrazzini G, Pasotti E, Muzzarelli S, Dequarti MC, Murzilli R, et al.3D TEE during catheter-based interventions. JACC Cardiovasc Imaging. 2014;7(3):292–308 . http://dx.doi.org/10.1016/j.jcmg.2013.10.012 PubMed
24 Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C, et al.Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052–61 . http://dx.doi.org/10.1016/j.jacc.2013.02.094 PubMed
25 Romano Mauri, Roman Burkart, Claudio Benvenuti, Maria Luce Caputo, Tiziano Moccetti, Alessandro Del Bufalo, Augusto Gallino, Carlo Casso, Luciano Anselmi, Tiziano Cassina, Catherine Klersy, and Angelo Auricchio Better management of out-of-hospital cardiac arrest increase survival rate and improves neurological outcome in the Seiss Canton Ticino Europace 2016 Mar;18(3):398-404 (Epub 2015 Sep 7).
26 Caputo ML, Regoli F, Conte G, Adjibodou B, Svab S, Del Bufalo A, et al.Temporal trends and long term follow-up of implantable cardioverter defibrillator therapy for secondary prevention: A 15-year single-centre experience. Int J Cardiol. 2017;228:31–6 . http://dx.doi.org/10.1016/j.ijcard.2016.11.071 PubMed
27 Conte G, Caputo ML, Regoli F, Marcon S, Klersy C, Adjibodou B, et al.True idiopathic ventricular fibrillation in out-of-hospital cardiac arrest survivors in the Swiss Canton Ticino: prevalence, clinical features, and long-term follow-up. Europace. 2017;19(2):259–66. PubMed
28 Nguyên UC, Maffessanti F, Mafi-Rad M, Conte G, Zeemering S, Regoli F, et al.Evaluation of the use of unipolar voltage amplitudes for detection of myocardial scar assessed by cardiac magnetic resonance imaging in heart failure patients. PLoS One. 2017;12(7):e0180637 . http://dx.doi.org/10.1371/journal.pone.0180637 PubMed
29 Tiziano Moccetti, Daniel Sürder, Catherine Klersy, Giuseppe Vassalli, Carmen Crljenica, Maria Grazia Rossi, Elena Pasotti, Gianni Soldati Sustained improvement in left venticular function after bone marrow-derived cell therapy in patients with acute ST elevation myocardial infarction a 5-year follow-up from the Stem Cell Transplantation in Ischaemic Myiocardium Study Swiss Med Wekly 2012 Jul25;142
30 Sürder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, et al.Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation. 2013;127(19):1968–79 . http://dx.doi.org/10.1161/CIRCULATIONAHA.112.001035 PubMed
31 Barile L, Moccetti T, Marbán E, Vassalli G. Roles of exosomes in cardioprotection. Eur Heart J. 2017;38(18):1372–9. PubMed
32 Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, et al.CHART Program. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38(9):648-660.. doi:. http://dx.doi.org/10.1093/eurheartj/ehw543
33 Bardelli S, Astori G, Sürder D, Tallone T, Terzic A, Soldati G, et al.Stem cell update: highlights from the 2010 Lugano Stem Cell Meeting. J Cardiovasc Transl Res. 2011;4(2):192–9 . http://dx.doi.org/10.1007/s12265-010-9232-4 PubMed
34 T. Moccetti, A. Maseri, A. Maggioni, et all Lugano Perspectives on Cardiovascular Research European Heart Journal Supplement – The Heart of the Matter – Vol 20 Supplement C, April 2018